STUDY ON IMPACT OF THE COPEPTIN IN THE DIAGNOSIS OF MALE PATIENTS WITH ACUTE CORONARY SYNDROME

Mohammed Atiyah Dakhil, Shatha M.J Al-khateeb, Arshad F Ridha

Abstract


Back ground
Acute coronary syndrome is a potentially life-threatening condition that affects millions of individuals each year. The introduction of biomarkers has brought improvement for both diagnostic and management of cardiac patients.Timely diagnosis of acute coronary syndrome in the emergency department remains challenging ,because of its delayed increase in plasma in the early phase of myocardial infarction , there is proof that copeptin is possibly useful as a diagnostic and prognostic biomarker in various cardiovascular diseases.
Objective
This study carried out to evaluate serum copeptin levels in patients with acute coronary syndrome and healthy persons and study the correlation of these levels as indicator for patients with risk factors.
Patients & Methods:
A total (58) referred male patients with acute coronary syndrome were included in this study with age range (23-75year) and also included (30) healthy persons served as control with age range (27-70year). Random blood sugar ,lipid profile (total cholesterol, triglyceride, High density lipoprotein cholesterol and low- density lipoprotein cholesterol), troponin I, creatine kinase-MB and copeptin were measured for acute coronary syndrome patients and control .
Results
Serum copeptin and lipid profile were significant increased in acute coronary syndrome in comparison with control group, while the level of high density lipoprotein decreased in sick patients in comparison with control group. Negatively significant correlation was found between Ejection Fraction and serum copeptin in acute coronary syndrome patients. Positively significant correlation was found between copeptin, troponin , creatine kinase -MB.
Key words: Acute coronary syndrome, male patients, copeptin, lipid profile, troponin.


Full Text:

PDF

References


Bhuiya F, Pitts S, McCaig L. Emergency Department Visits for Chest Pain and Abdominal Pain: United states, 1999-2008. National Center for Health Statistics Data Brief. 2010.

O'ConnorRE, BradyW,BrooksSC,et al. "Part 10:acute coronary syndromes:2010AmericanHeart Association Guidelins for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care". Circulation 2010; 122 (18 Suppl 3): S787–817.

Morgenthaler N.G. Copeptin: a biomarker of cardiovascular and renal function. Congest Heart Fail. 2010;16:S37–S44.

Nickel CH, Bingisser R.,Morgenthaler NG.”The role of copeptin as a diagnostic and prognostic biomarker for risk stratification in the emergency department. BMC Medicine. 2012;10:7.

Giannopoulos G, Deftereos S, Panagopoulou V, Kossyvakis C, Kaoukis A, Bouras G, et al. Copeptin as a biomarker in cardiac disease. Curr Top Med Chem. 2013;13:23140.

Elshafei A, Abdalla G, El-Motaal OA, Salman T. “Copeptin: a neuroendocrine biomarker in acute myocardial infarction”, Annual review & research in biology,2013,3(4),1040-54.

Kristyagita A, Siswanto BB. The role of copeptin as a novel cardiovascular biomarker. Medical Journal of Indonesia. 2015 Mar 18;24(1):59-66.

Thygesen K, Mair J, Katus H, Plebani M, Venge P, Collinson P, et al. Rec-ommendations for the use of cardiac troponin measurement in acute cardiac care. Eur Heart J. 2010;31(18):2197-204.

Mueller C. Detection of myocardial infarction - Is it all troponin? Role of new markers. Clin Chem. 2012;58(1):162-4.

Thygesen K, Alpert JS, Jaffe AS, Simoons ML, et al.: Writing Group on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction Third Universal Definition of Myocardi-al Infarction, J Am Coll Cardiol.2012, 61:1581–1598.

Gu YL, Voors AA, Zijlstra F, Hillege HL, Struck J, Masson S, et al. Comparison of the temporal release pattern of copeptin with conventional biomarkers in acute myocardial infarction. Clin Res Cardiol. 2011;100(12):1069-76.

David B. Sacks, Mark Arnold, George L. Bakris, David E. Bruns, Andrea Rita Horvath, M. Sue Kirkman, Ake Lernmark, Boyd E. Metzger, and David M. Nathan Diabetes Care. 2011 Jun; 34(6): e61–e99.

Alice T. C. R. Kiba Koumaré, Linda P. L. Sakandé, Elie Kabré, Issaka Sondé, Jacques imporé, Jean Sakandé Published: January 22, 2015.

Bogdanovic E et al. Endoplasmic reticulum stress in adipose tissue augments lipolysis. J Cell Mol Med (2015),19:82-91.

Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD, Remaley AT. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nature cell biology. 2011 Apr;13(4):423-33.

Warnick GR, Knopp RH, Fitzpatrick V, Branson L. Estimating low density lipoprotein cholesterol by the Friedewald equation is adequate for classifying patients on the basis of nationally recommended cutpoints. Clin Chem (1990), 36(1):15-19.

Apple FS, Smith SW, Pearce LA, Ler R, Murakami MM, Benoit MO, Levy C, Dumas C, Paul JL. Use of the bioMérieux VIDAS® troponin I ultra assay for the diagnosis of myocardial infarction and detection of adverse events in patients presenting with symptoms suggestive of acute coronary syndrome. Clinica Chimica Acta. 2008 Apr 1;390(1-2):72-5.

Penttilä K, Koukkunen H, Halinen M, Rantanen T, Pyörälä K, Punnonen K, Penttilä I. Myoglobin, creatine kinase MB isoforms and creatine kinase MB mass in early diagnosis of myocardial infarction in patients with acute chest pain. Clinical biochemistry. 2002 Nov 1;35(8):647-53.

El Sayed ZH, Mahmoud HA, El Shall LY, El Sheshtawey FA, Mohamed MA. Impact of copeptin on diagnosis of acute coronary syndrome. Egyptian Journal of Medical Human Genetics. 2014;15(3):241-7.

Wang G, Wang S, Sun L, Chai H, Li J, Zhang G. Pregnancy-associated plasma protein A and copeptin as markers in the early diagnosis of acute coronary syndrome. Int J Clin Exp Med. 2016 Jan 1;9(6):12073-8.

Özalp B, Caglar FN, Karakurt H, Bıyık İ, Ertürk M, Yıldırım MR, Işıksaçan N, Baycan ÖF, Yazan S. Correlations between hematological indicators and other known markers in acute coronary syndromes. EJCM. 2017 Dec 15;5(4):67-74.

Mirghani HO. Age related differences in acute coronary syndrome presentation and in hospital outcomes: a cross-sectional comparative study. The Pan African medical journal. 2016;24.

Yu S, Yang H, Guo X, Zhang X, Zheng L, Sun Y. Prevalence of dyslipidemia and associated factors among the hypertensive population from rural Northeast China. BMC Public Health. 2015;15:1152.

Ibrahim ,M. , Ibrahim , A. , Shaheen , K. and Nour , M. ( 2013) : Lipid profile in Egyptian patients with coronary artery disease , The Egyptian Heart Journal ; 65:79– 85 .

Kumar VS, Sreelatha M. Clinical Study of Lipid Profile Pattern in Acute Coronary Syndromes. Int J Sci Stud 2017;5(4):174-178.

Wang Y, Xu D. Effects of aerobic exercise on lipids and lipoproteins. Lipids in health and disease. 2017 Dec;16(1):132.

Prabodh V., Chowdary N., Reddy R., Shekhar R., and Vidya D.: Lipid Profile Levels On The Second Day Of Acute Myocardial Infarction, International Journal of Pharmacological and Biological Sciences, 2012; 3(3): 245-50.

Kulkarni J. and , Phalak P., “Study of Oxidative Stress and Lipid Profile in Coronary Artery Diseases”,, International Journal of Research in Pharmaceutical and Biomedical Sciences, 2013; 4(2): 624-7.

Mahmoud MA, Shaaban MA, Ramzy AA. Clinical role of serum Copeptin in acute coronary syndrome. The Egyptian Heart Journal. 2018 May 10.

Sarkari ,M.,and Jaiswal,M” Epidemiological profile and predictors of mortality in acute coronary syndrome: a prospective study”. Int J Adv Med. 2018 ;5(3):710-715.

Alan H.B. Wu ,”Release of cardiac troponin from healthy and damaged myocardium”, Frontiers in Laboratory Medicine ,2017,(1), 144–150.

Maisel A, Muller C, Neath S, et al.. Copeptin helps in the early detection of patients with acute myocardial infarction. JACC. 2013;62:150–160.

Slagman A, Searle J, Müller C, Möckel M. et al. Temporal release pattern of copeptin and troponin T in patients with suspected acute coronary syndrome and spontaneous acute myocardial infarction. Clin Chem. 2015;61:1273–1282.

Keller T, Tzikas S, Zeller T, Czyz E, Lillpopp L, Ojeda FM, et al. Copeptin improves early diagnosis of acute myocardial infarction. J Am Coll Cardiol 2010;55:2096–106.

Charpentier S, Maupas‐Schwalm F, Cournot M, Elbaz M, Botella JM, Lauque D. Combination of Copeptin and Troponin Assays to Rapidly Rule Out Non‐ST Elevation Myocardial Infarction in the Emergency Department. Academic Emergency Medicine. 2012 May;19(5):517-24.

Folli C, Consonni D, Spessot M, Salvini L, Velati M, Ranzani Diagnostic role of copeptin in patients presenting with chest pain in the emergency rroom Eur J Int Med. 2013;24:189–193.

Balmelli C, Meune C, Twerenbold R, et al.. Comparison of the performances of cardiac troponins, including sensitive assays, and copeptin in the diagnosis of acute myocardial infarction and long-term prognosis between women and men. Am Heart J. 2013;166:30–37.

Möckel M. Copeptin adds to high-sensitivity troponin T in rapid rule out of acute myocardial infarction. Clin Chem. 2012;58:306–307.

Nursalim A, Suryaatmadja M, Panggabean M. Potential clinical application of novel cardiac biomarkers for acute myocardial infarction. IJIM. 2013;45:136–149.


Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.